Sudden cardiac death remains a leading cause of death in the Western world, accounting for up to 20% of all deaths in the United States. The major causes of sudden cardiac death in adults age 35 and older are coronary artery disease (70% to 80%) and dilated cardiomyopathy (10% to 15%). At the molecular level, a wide variety of mechanisms contribute to arrhythmias that cause sudden cardiac death, ranging from genetic predisposition (rare mutations and common polymorphisms in ion channels and structural proteins) to acquired electrophysiological and structural remodeling in left ventricular hypertrophy and failure. A growing body of evidence suggests that altered ion channel function is closely linked to changes in metabolic activity in a wide variety of pathologic conditions. In this review we focus on the mechanisms by which altered metabolic function affects cardiac electrophysiology. We will review the specific molecular targets that allow cardiomyocytes to recognize alterations in their metabolic state and translate this information into changes in membrane excitability in various pathophysiological conditions including ischemia-reperfusion, heart failure (HF), left ventricular (LV) hypertrophy, diabetic cardiomyopathy, and atrial fibrillation (AF). A comprehensive understanding of the interrelated processes of metabolic and electric remodeling promises to identify new molecular targets for the treatment of cardiac arrhythmias.

1. Maintenance of Sodium and Calcium Homeostasis Is Critical for Electric Stability
Free energy released from the hydrolysis of high-energy phosphates is essential for maintenance of cellular homeostasis. Maintenance of Na⁺ and K⁺ gradients across the plasma membrane is among the most energy-intensive cellular processes in the heart. Ultimately, all transmembrane ionic movements are driven by the free energy released from ATP hydrolysis by P-type (“P” for phosphorylated intermediate) ATPases, including the Na⁺-K⁺-ATPase and the sarcoplasmic reticulum Ca²⁺-ATPase. The electrochemical gradient generated by the Na⁺-K⁺-ATPase establishes the gradients of Na⁺ and K⁺ across the sarcolemma, thus establishing the driving force for the passage of these ions across the myocyte cell membrane through voltage-dependent ion-selective channels. The energy stored in the electrochemical Na⁺ gradient is used to move other ions across the sarcolemma. For instance, it provides the driving force for Ca²⁺ removal from the cytoplasm to the extracellular space via the Na⁺-Ca²⁺ exchanger (NCX1 encoded by SLC8A1). Removal of Ca²⁺ during diastole is also achieved through a second P-type ATPase located in the sarcoplasmic reticulum membrane (SERCA2 encoded by ATP2A2), which transports Ca²⁺ from the cytosol of the cell to the lumen of the sarcoplasmic reticulum (SR) at the expense of ATP hydrolysis during muscle relaxation.

Under physiological conditions, ATP is mainly supplied by mitochondrial oxidative phosphorylation and to a lesser degree by glycolysis. Commensurate with the large metabolic demand of contraction of the heart, mitochondria occupy approximately 30% of the volume of ventricular cardiomyocytes and form a network around the myofilaments, thus placing the sites of ATP production immediately adjacent to the sites of ATP consumption. The critical dependence of the ion homeostasis on sufficient energy supply becomes evident in pathophysiological conditions as diverse as ischemia/reperfusion, HF, and ventricular hypertrophy, in which a mismatch in ATP supply and ATP utilization may lead to electric and mechanical instability.

During severe ischemia, for instance, oxidative metabolism comes to a halt. Even though anaerobic glycolysis increases in a compensatory fashion, this process is unable to supply sufficient amounts of ATP to maintain long-term viability and function. As a consequence, concentrations of ATP may fall by more than 70% within 20 minutes after onset of ischemia, thereby limiting the function of the Na⁺-K⁺-ATPase, reducing the extrusion of sodium ions, and dissipating the transmembrane ion and voltage gradients. Anaerobic glycolysis may further aggravate intracellular sodium loading because accumulating protons (generated from lactate) activate the Na⁺-H⁺-exchanger (NHE1 encoded by SLC9A1), which exchanges intracellular H⁺ for extracellular Na⁺. Metabolic inhibition, as observed in ischemia, also promotes opening of connexin-43 hemichannels. Connexin proteins are assembled together in groups of 6 to form hemichannels (or connexons), which can either combine end-to-end to form gap junction channels or occur as single connexons in nonjunctural regions. If activated in the nonjunctural plasma membrane by metabolic inhibition, hemichannels are nonselective cation channels and permit K⁺, Na⁺, and Ca²⁺ to move down their respective electrochemical gradients across the sarcolemma. Based on their large unitary conductance (120pS) and high open probability, evidence suggests that...
only a small number of open connexin-43 hemichannels is sufficient to double the Na\(^+\) influx of a normal beating myocyte.\(^{10,11}\) The notion that intracellular sodium ([Na\(^+\)]\(_i\)) overload contributes to electric instability is supported by the fact that high [Na\(^+\)]\(_i\) has been found to be a strong predictor of ventricular fibrillation (VF) in experimental models of myocardial ischemia.\(^{12}\) In addition to ischemia, profound metabolic abnormalities with elevation of [Na\(^+\)]\(_i\) are also encountered in pathophysiological states as diverse as LV hypertrophy, HF, or diabetes mellitus—all of which are associated with an increased incidence of arrhythmias.\(^{13–15}\) In diabetes, it has been shown that hyperglycemia directly inhibits the Na\(^+\)/H\(^+\)-ATPase,\(^{16}\) thus promoting intracellular Na\(^+\) overload. In LV hypertrophy and HF, a rise in [Na\(^+\)]\(_i\) may partially compensate for depressed contractility by raising cytosolic Ca\(^{2+}\) via the reverse-mode NCX1-current.

Intracellular Na\(^+\) loading is linked to arrhythmias by a number of mechanisms, as summarized in Figure 1: First, intracellular Na\(^+\) accumulation leads to net K\(^+\) loss because of the need to maintain electroneutrality and osmotic balance.\(^{17}\) Accumulation of extracellular K\(^+\) not only promotes diastolic injury currents, which trigger extrasystoles, but also progressively slows conduction and alters refractoriness, generating both the trigger and substrate for reentry.\(^{18}\) Second, elevation of [Na\(^+\)]\(_i\), may further exacerbate a mitochondrial energetic deficit, observed in various pathophysiological states. Recent evidence suggests that cardiac mitochondria take up Ca\(^{2+}\) rapidly via the Ca\(^{2+}\)-uniporter (MCU).\(^{19}\) Under physiological conditions, the extrusion rate of mitochondrial calcium from the mitochondrial matrix via the mitochondrial sodium-calcium exchanger (mNCX) is slower than the mitochondrial Ca\(^{2+}\) uptake,\(^{19,20}\) so that, at higher heart rates, Ca\(^{2+}\) accumulates in the mitochondrial matrix, activating several enzymes of the tricarboxylic acid (TCA) cycle and increasing NADH production. Together with the high-energy phosphotransfer enzymes creatine kinase (CK) and adenylate kinase (AK), mitochondrial Ca\(^{2+}\) accumulation thereby facilitates the matching of NADH/NAD\(^+\) redox potential to ATP production in periods of increased energetic demand.\(^{21}\) The balance between mitochondrial uptake and release of Ca\(^{2+}\) can be modified by a variety of factors, including mitochondrial inorganic phosphate, ADP, and [Na\(^+\)]\(_i\).\(^{22,23}\) In conditions in which cytosolic Na\(^+\) is elevated, the decay rate of the mitochondrial calcium transient is increased and mitochondrial Ca\(^{2+}\) accumulation is impaired as more calcium is extruded via the mitochondrial NCX.\(^{19,22}\) Consequently, high intracellular Na\(^+\) will lead to a vicious cycle exacerbating the mismatch between ATP demand and ATP supply, as the reduction of Ca\(^{2+}\) in the mitochondrial matrix leads to NADH oxidation.\(^{19}\)

Finally, elevation of [Na\(^+\)]\(_i\) in myocardial ischemia and reperfusion activates reverse-mode Na\(^+\)/Ca\(^{2+}\) exchanger, thereby promoting intracellular calcium overload, as the cell exchanges 3 sodium ions for 1 calcium ion.

2. Metabolic Alterations of Calcium Homeostasis and Excitation-Contraction Coupling

After the rapid depolarization of the action potential, Ca\(^{2+}\) enters the cell via L-type calcium channels (I\(_{\text{Ca,L}}\)) and triggers calcium-induced calcium release from the sarcoplasmic reticulum. During metabolic inhibition, multiple studies have documented a reduction of the amplitude of I\(_{\text{Ca,L}}\) in ventricular myocytes of guinea pigs,\(^{24,25}\) rats,\(^{26}\) and rabbits,\(^{27,28}\) thought to have important functional consequences: First, the reduction in I\(_{\text{Ca,L}}\) contributes to shortening of the action potential (AP) duration during ischemia together with activation of sarcolemmal K\(_{\text{ATP}}\) channels (see Section 4). However, the overall contribution of I\(_{\text{Ca,L}}\) to shortening of the AP during ischemia is still a matter of debate, as modeling studies suggest that I\(_{\text{K,ATP}}\) is the only process that could decrease action potential duration by more than 50% and reproduce AP shape changes that are observed experimentally.\(^{29}\) Second, reduction in I\(_{\text{Ca,L}}\) amplitude will decrease the calcium-
induced calcium release from the sarcoplasmic reticulum. Metabolic inhibition, intracellular acidification, a reduction in ATP, and a rise in ADP concentrations will increase the cytoplasmic free calcium ([Ca\(^{2+}\)]\(_{i}\)) and inhibit both the SR Ca\(^{2+}\) uptake (via SERCA2)\(^{31}\) and the SR Ca\(^{2+}\) release (via the ryanodine receptor RyR2)\(^{31-33}\); thus, the net effect on the calcium transient is complex and multifactorial. Overall, in ischemia the reduction in SR Ca\(^{2+}\) release appears to predominate over the reduction in SR Ca\(^{2+}\) uptake, manifest as a decrease in the frequency of spontaneous release of Ca\(^{2+}\) via RyR2\(^{31}\) and a marked decrease in the area of the cell exhibiting organized Ca\(^{2+}\) release.\(^{34}\) Consequently, SR Ca\(^{2+}\) content tends to increase during metabolic stress and ischemia.\(^{31}\) On reperfusion, removal of the inhibitory effect on RyR2 could give rise to spontaneous arrhythmogenic waves of Ca\(^{2+}\) release. Perhaps more importantly, these complex alterations in subcellular Ca\(^{2+}\) handling have been implicated in the genesis of calcium transient (CaT) alternans, which can give rise to AP- or T-wave alternans, preceding VF.\(^{35-37}\)

Figure 2. Transcriptional coregulatory patterns for SERCA2 (ATP2A2) and RyR2 in mouse myocardium. Genes that were coregulated with SERCA2 and RyR2 were identified by StarNet\(^{102}\) and grouped into Gene Ontology categories. Mitochondrial transcripts showed the most significant coexpression pattern with SERCA2 and RyR2. Bonferroni corrected probability values for the correlation coefficient across 239 mouse microarrays are indicated. OXPHOS indicates oxidative phosphorylation.

3. Metabolic Activity Alters Expression and Function of Repolarizing Potassium Currents

Besides regulating intracellular Na\(^+\) and Ca\(^{2+}\) homeostasis, metabolic activity has also been shown to critically affect repolarizing K\(^+\) currents. Other than \(K_{ATP}\), one of the first K\(^+\) channels recognized to be modulated by metabolic inhibition was the Ca\(^{2+}\)-independent transient outward K\(^+\) current, \(I_{to}\). Inhibition of oxidative phosphorylation, using inhibitors such as 2,4-dinitrophenol (DNP) and cyanide, markedly decreased the magnitude of the 4-AP-sensitive \(I_{to}\).\(^{42}\) Remodeling of cardiac \(I_{to}\) has also been implicated in diabetes mellitus, one of the leading metabolic abnormalities associated with arrhythmias. Compared with healthy individuals, diabetic patients show a higher incidence of AF, VF, and sudden cardiac death.\(^{14,43}\) Electrocardiographically, diabetic patients often display QT-interval prolongation and T-wave abnormalities.\(^{14}\) Studies designed to elucidate the cellular mechanisms of diabetes-induced repolarization abnormalities have consistently demonstrated AP prolongation in myocytes isolated from diabetic animals. This was mainly due to a net decrease in outward repolarizing currents, including \(I_{to}\).\(^{44-46}\) A primary role of metabolic changes in regulation of \(I_{to}\) is suggested because downregulation of \(I_{to}\) in cardiomyocytes from diabetic hearts could be reversed by short-term treatment with insulin.\(^{44}\) Recent studies have shed some light on the mechanisms by which diabetes mellitus alters the functional expression of cardiac ion channels. Peroxisome proliferator-activated receptor \(\alpha\) (PPAR\(\alpha\)), a key regulator of
fatty acid and glucose metabolism, is upregulated in diabetic hearts and has been found to lead to remodeling of a wide variety of ion channels, most prominently I\textsubscript{to}.\textsuperscript{47} Transgenic mice with chronic, cardiac-specific activation of PPAR\textsubscript{\alpha} displayed decreased I\textsubscript{to} density, concomitant with reduced protein expression of the \(\alpha\)- (KCND2) and \(\beta\)- (KCNIP2) subunits of I\textsubscript{to} channels.\textsuperscript{47} In contrast, transgenic animals with deletion of the PPAR\textsubscript{\alpha} gene showed increased density of I\textsubscript{to}.\textsuperscript{47} Of note, in PPAR\textsubscript{\alpha}-overexpressing animals, these changes occurred well before any signs of LV hypertrophy or LV dysfunction became apparent, suggesting that altered metabolic activity directly affects expression of I\textsubscript{to}. In addition to upregulation of PPAR\textsubscript{\alpha}, a rise in plasma free fatty acids in diabetes mellitus increases the rate of \(\beta\)-oxidation. Amphiphilic fatty acid metabolites, such as palmitoylcarnitine and palmitoyl-CoA, have been shown to directly suppress I\textsubscript{to} in rodents.\textsuperscript{48} Activation of neurohormonal systems, including the renin-angiotensin system, also contribute to potassium channel remodeling in the diabetic heart.\textsuperscript{49} Likewise, diabetes-induced downregulation of I\textsubscript{to} involves the formation of reactive oxygen species (ROS), and incubation of cells isolated from diabetic hearts with reduced glutathione (GSH) was able to reverse downregulation of I\textsubscript{to}.\textsuperscript{44} Although most of these studies have been carried out in rodents, recent studies demonstrate that diabetes-induced remodeling of potassium channels also holds true for larger mammals, which share a far greater similarity of ventricular repolarization to humans. In dogs, for instance, diabetes-induced repolarization abnormalities were associated with prominent downregulation of I\textsubscript{to}.\textsuperscript{50} Likewise, diabetes-induced downregulation of I\textsubscript{to} involves the formation of reactive oxygen species (ROS), and incubation of cells isolated from diabetic hearts with reduced glutathione (GSH) was able to reverse downregulation of I\textsubscript{to}.\textsuperscript{44}

4. Sarcolemmal ATP-Dependent Potassium Channels Link Metabolic Activity to Excitability

Sarcolemmal ATP-dependent potassium (K\textsubscript{ATP}) channels act as immediate metabolic sensors, coupling electric excitability to the cellular high-energy phosphate pool of cardiomyocytes. These channels occur in high density in ventricular cardiomyocytes and are hetero-octamers composed of the pore-forming Kir6.2 (KCNJ11) subunits and the regulatory sulfonylurea receptor SUR2A (ABCC9).\textsuperscript{51–53} ATP is the main inhibitory channel ligand that binds to Kir6.2 subunits and keeps the channel closed under physiological conditions when intracellular ATP levels are high (≈6 to 10 mmol/L). O’Rourke et al\textsuperscript{54} described repetitive and self-sustaining oscillations of IK\textsubscript{ATP} that were closely associated with cyclic changes in the mitochondrial NADH/NAD\textsuperscript{+} redox state in cardiac myocytes subjected to metabolic stress. However, glycolytically generated ATP appears to be more critical in regulating IK\textsubscript{ATP} in mammalian ventricular myocytes than ATP generated by oxidative phosphorylation.\textsuperscript{55} These observations were complemented by recent data showing that glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a key glycolytic enzyme, serves as an accessory protein of the cardiac sarcolemmal K\textsubscript{ATP} channel complex.\textsuperscript{56,57} The physical association between Kir6.2 and GAPDH may have significant functional consequences on the K\textsubscript{ATP} channel, as this enzyme catalyzes the reaction of 1,3-bisphosphoglycerate production. 1,3-Bisphosphoglycerate has been suggested to be an endogenous K\textsubscript{ATP} channel opener that has the ability to activate sarcolemmal K\textsubscript{ATP} channels even in the presence of high levels of intracellular ATP.\textsuperscript{58} Modulation of ATP binding by additional metabolic factors is also suggested by a 2-fold–higher IC\textsubscript{50} for ATP-dependent inhibition of K\textsubscript{ATP} channels in diabetic hearts compared with controls.\textsuperscript{59} As a result, hypoxia-induced shortening of the AP caused by activation of the K\textsubscript{ATP} channels occurs to a much greater extent in ventricular cells from diabetic rats.\textsuperscript{60} Of note, this sudden increase in K\textsubscript{ATP} conductance during ischemia is expected to produce a greater dispersion of refractoriness in
the diabetic versus nondiabetic heart, as AP prolongation caused by downregulation of major repolarizing K⁺ channels is characteristically seen in diabetic myocardium (see Section 3).

During hypoxia or ischemia, global and especially local ATP concentrations may fall below a critical level, leading to opening of the KATP channel. Interestingly, the ST-segment elevation often observed on the ECG in the ischemic heart is postulated to result from excess opening of ATP-sensitive potassium channels. As ROS can be highly toxic to mitochondria, with ROS implicated as key signal transducers. As a result, a local collapse of the mitochondrial membrane potential can have an impact on the entire mitochondrial network. As variations in ΔΨm and AP duration are highly correlated through opening of sarcolemmal KATP channels, large regions of conduction block may be created in the setting of ischemia/reperfusion, producing a substrate for stable arrhythmias on reperfusion. Therefore, this “metabolic sink” would be distinct from other forms of block of electric propagation, including loss of cell-cell coupling by closure of gap junctions, regional uncoupling by anatomic barriers to conduction (eg, scar tissue), or dynamic functional block due to heterogeneity of intrinsic electrophysiological restitution properties.

6. Role of Non–Ion Channel Genes Linking Metabolic Activity to Arrhythmias

Adenosine monophosphate–activated protein kinase (AMPK) is a serine/threonine kinase abundantly expressed in myocardial tissue. It is composed of a catalytic α-subunit and regulatory β- and γ-subunits assembled as a heterotrimer. AMP-activated protein kinase functions as a metabolic sensor in cardiomyocytes. AMPK activation by an elevated ratio of AMP to ATP stimulates ATP-generating pathways and downregulates ATP-consuming pathways. Therefore, AMPK has been termed the “guardian of energy status” in the heart. Specific mutations in the γ2 regulatory subunit of AMP-activated protein kinase (PRKAG2) have been shown to alter myocardial AMPK activity and cause a glycogen storage cardiomyopathy characterized by ventricular preexcitation, AF, progressive conduction system disease, and a variable degree of LV hypertrophy. The structural abnormalities, including glycogen accumulation and LV hypertrophy, suggest that electrical instability associated with PRKAG2 mutations might arise secondary to extensive structural remodeling rather than as a primary result of the PRKAG2 mutation. In this sense, it has been suggested that glycogen-filled cardiomyocytes contribute to the formation of muscular bundles between atria and ventricles that mediate ventricular preexcitation. Alternatively, the high incidence of ventricular preexcitation and atrioventricular conduction abnormalities observed across several metabolic gene defects may result from disruption of the developmental patterning of the atrioventricular ring. The notion that arrhythmias arise secondary to structural abnormalities has been challenged by the discovery of a family with a mutation in PRKAG2, in which affected family members displayed an arrhythmogenic phenotype starting in early childhood at a time when structural abnormalities and cardiac hypertrophy were absent. Mechanistically, AMPK could directly modulate the activity of sarcolemmal ion channels, as demonstrated for the cardiac sodium channel. Additionally, AMPK activity could affect electrophysiological processes via a wide variety of intracellular signaling pathways. Most notably, AMPK can phosphorylate endothelial nitric oxide synthase and p38 MAP kinase, both of which have pleiotropic actions in the heart, including direct effects on ion channels. Even though the precise cellular mechanisms linking AMPK mutations to arrhythmias are still elusive, the finding that a mutation in a
major regulator of cardiac energy metabolism causes arrhythmogenic activity supports the notion that alterations in cardiac bioenergetics are sufficient to cause arrhythmias independent of a precipitating event such as ischemia/reperfusion.

In addition to AMPK mutations, several monogenic disorders affecting genes of lipid and glycogen metabolism present with arrhythmias. For instance, Bonnet et al. reported a series of 24 children in whom arrhythmias or conduction defects were the presenting symptom of various fatty acid oxidation disorders. They suggested that the accumulation of arrhythmogenic intermediary metabolites of fatty acids, such as long-chain acylcarnitines, may be responsible for arrhythmias. However, these rare inherited disorders of fatty acid metabolism are commonly associated with cardiomyopathy, making it difficult to separate the arrhythmogenic predisposition from the underlying HF.

7. Altered Metabolism in Atria: Cause and Consequence of Arrhythmias

Cha et al. have demonstrated that the propensity for sustained AF in dogs with pacing-induced HF robustly correlates with the cellular energetic state in the atria. Failing atrial myocardium displays a profound bioenergetic deficit with reduced activities of the phosphotransfer enzymes CK and AK and depletion of high-energy phosphates. Despite significant increases in the atrial effective refractory period in failing hearts, an enhanced propensity to sustained AF was observed in HF. Intriguingly, AF duration correlated inversely with atrial ATP concentration as well as with AK and CK activity. Likewise, atrial tissue samples from patients who had AF after surgery had significantly lower concentrations of glucose, β-hydroxybutyrate, and acetate compared with patients who remained in sinus rhythm after surgery. These observations suggest that perturbations in bioenergetic homeostasis and myocardial substrate use contribute to electrical instability in atrial myocardium.

There is a growing body of evidence that metabolic activity and arrhythmias are interdependent: An impaired cellular energetic state not only predisposes to atrial arrhythmias, but atrial rhythm disturbances also influence metabolic activity. Transcriptomic studies in permanent human AF, for instance, identified a prominent dysregulation of transcripts with metabolic function in tissue samples from patients with AF compared with patients in sinus rhythm. Notably, there was a coordinated transcriptional downregulation of enzymes controlling fatty acid oxidation and concomitant upregulation of enzymes involved in glucose utilization. In a goat model of AF, phosphocreatine decreased by 60% in atrial myocytes after 1 week of AF, suggesting an enhanced demand for high-energy phosphates. As phosphocreatine levels increased thereafter and returned to baseline levels after 16 weeks of AF, compensatory mechanisms are assumed to be activated to restore the metabolic balance between energy demand and supply. The finding of a prominent upregulation of transcripts involved in metabolic processes in human and experimental models of AF supports this notion. Consistent with these microarray expression data, a recent proteomic study of human atrial AF samples showed that the majority of changes observed in fibrillating atria were related to energy metabolism.

8. Correction of Metabolic Abnormalities: A Novel Antiarrhythmic Strategy?

Data reviewed in this article have highlighted that altered metabolism can lead to arrhythmias via a variety of cellular pathways in myocardial cells. Life-threatening ventricular tachyarrhythmias are prevalent in virtually every cardiovascular condition associated with structural and/or functional abnormalities. Clinical trials such as CAST and SWORD revealed that, at least in postinfarction patients, ion channel–targeted antiarrhythmic therapy may lead to increased rather than reduced mortality rates. In AF, large clinical trials have failed to prove the superiority of a “rhythm control” over a “rate control strategy” possibly due to an increased mortality rate associated with antiarrhythmic therapy. Thus, modulating only the electric activity (ie, ion channel function) has proven ineffective to prevent arrhythmias in the long term. Instead, additional strategies are needed to correct the underlying pathophysiological processes and metabolic abnormalities that lead to maladaptive ion channel remodeling.

In this respect, several drugs that either increase metabolic efficiency by augmenting glucose metabolism and blocking muscle mitochondrial free fatty acid uptake (eg, perhexiline, trimetazidine, ranolazine) and/or block late sodium currents (ranolazine) have shown benefits in small preliminary clinical trials. Moreover, emerging evidence regarding the central role of mitochondria in maintaining electrical stability in the heart has led to the identification of several novel pharmacological targets. For instance, 4′-chlorodiazepam, a ligand of the mitochondrial benzodiazepine receptor, has been proven effective in stabilizing the mitochondrial membrane potential primarily by blocking the mitochondrial inner membrane anion channel (IMAC) at the time of increased oxidative stress and protect against reperfusion arrhythmias and postischemic contractile impairment. Remarkably, unlike other preconditioning agents, 4′-chlorodiazepam was effective when given as a single bolus on reperfusion.

Conclusion

It is apparent that there is an intimate relationship between energy metabolism and ion homeostasis. The varied ways in which altered metabolism can be arrhythmogenic provides valuable mechanistic insights and identifies potential molecular targets for pharmacological interventions to treat arrhythmias. Given the proarrhythmic risk associated with conventional, ion channel–targeted antiarrhythmic drug therapies, a new approach to arrhythmias is urgently needed. In this respect, correction of the cellular bioenergetic deficit associated with structural heart disease might represent a novel and promising antiarrhythmic strategy.

Sources of Funding

This work was supported by National Institutes of Health grants NHLBI R33, HL087363, and PO1 HL077180. Dr. Tomaselli is supported by the Michel Mirowski MD Professorship in Cardiology.


Key Words: metabolism ▪ ischemia ▪ diabetes mellitus ▪ arrhythmia ▪ ion channels
Cardiac Metabolism and Arrhythmias
Andreas S. Barth and Gordon F. Tomaselli

Circ Arrhythm Electrophysiol. 2009;2:327-335
doi: 10.1161/CIRCEP.108.817320

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circep.ahajournals.org/content/2/3/327

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation: Arrhythmia and Electrophysiology can be obtained via RightsLink, a service of the Copyright
Clearance Center, not the Editorial Office. Once the online version of the published article for which
permission is being requested is located, click Request Permissions in the middle column of the Web page
under Services. Further information about this process is available in the Permissions and Rights Question and
Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Arrhythmia and Electrophysiology is online at:
http://circep.ahajournals.org//subscriptions/